FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2609143407> ?p ?o ?g. }

• W2609143407 endingPage "e0176004" @default.
• W2609143407 startingPage "e0176004" @default.
• W2609143407 abstract "Malaria, particularly due to Plasmodium falciparum, remains a major public health threat in Ethiopia. Artemether-lumefantine (AL) has been the first-line antimalarial drug against uncomplicated P. falciparum malaria in the country since 2004. Regular monitoring of antimalarial drugs is recommended by the World Health Organization (WHO) to help early detection of drug resistant strains of the parasite and contain their rapid spread. The objective of this study was to assess the therapeutic efficacy of AL in a high-transmission setting in Ethiopia. The study site was Setit Humera, northwest Ethiopia. Single-arm prospective study of a 28-day follow-up was conducted from October 2014 to January 2015 according to the revised WHO 2009 drug efficacy study protocol. Study end-points were classified into primary end-point and secondary end-point. While the primary end-point was the day-28 adequate clinical and parasitological response the secondary end-points were clinical and parasitological evaluations (parasite, fever and gametocyte clearance rate, incidence of drug adverse events) and the relative increment in hemoglobin (Hb) level from baseline to day (D) 14 and D28. A total of 92 patients were enrolled and 79 had completed the 28-day follow-up period. The overall cure rate was 98.8% with 95% confidence interval of 0.915-0.998 without polymerase chain reaction correction. The parasite clearance rate was high with fast resolution of clinical symptoms; 100% of the study participants cleared parasitaemia and fever on D3. Gametocyte carriage was reduced from 7% on D0 to 1% on D3 and complete clearance was achieved on D14. Mean Hb concentration significantly increased on D28 compared to that on D14. There was no serious adverse event. AL was efficacious and safe in a high-transmission setting for treatment of uncomplicated falciparum malaria." @default.
• W2609143407 created "2017-05-05" @default.
• W2609143407 creator A5006130540 @default.
• W2609143407 creator A5044602450 @default.
• W2609143407 creator A5052744307 @default.
• W2609143407 creator A5083131417 @default.
• W2609143407 creator A5090342457 @default.
• W2609143407 date "2017-04-26" @default.
• W2609143407 modified "2023-09-24" @default.
• W2609143407 title "Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia" @default.
• W2609143407 cites W1500098329 @default.
• W2609143407 cites W1552753591 @default.
• W2609143407 cites W1600702291 @default.
• W2609143407 cites W1697297771 @default.
• W2609143407 cites W1819925427 @default.
• W2609143407 cites W1822671023 @default.
• W2609143407 cites W1903447473 @default.
• W2609143407 cites W1964075666 @default.
• W2609143407 cites W1968329346 @default.
• W2609143407 cites W1990484067 @default.
• W2609143407 cites W1991442399 @default.
• W2609143407 cites W1995029436 @default.
• W2609143407 cites W2001500896 @default.
• W2609143407 cites W2002469675 @default.
• W2609143407 cites W2011052290 @default.
• W2609143407 cites W2014186251 @default.
• W2609143407 cites W2038101188 @default.
• W2609143407 cites W2062416225 @default.
• W2609143407 cites W2091551182 @default.
• W2609143407 cites W2109480282 @default.
• W2609143407 cites W2109827189 @default.
• W2609143407 cites W2111813303 @default.
• W2609143407 cites W2116510803 @default.
• W2609143407 cites W2119156545 @default.
• W2609143407 cites W2141190197 @default.
• W2609143407 cites W2146285118 @default.
• W2609143407 cites W2147783946 @default.
• W2609143407 cites W2148420565 @default.
• W2609143407 cites W2154591666 @default.
• W2609143407 cites W2155517825 @default.
• W2609143407 cites W2156970877 @default.
• W2609143407 cites W2160957670 @default.
• W2609143407 cites W2163117814 @default.
• W2609143407 cites W2170434008 @default.
• W2609143407 cites W2171102256 @default.
• W2609143407 cites W2172459683 @default.
• W2609143407 cites W2289660161 @default.
• W2609143407 cites W2344718652 @default.
• W2609143407 cites W2397073176 @default.
• W2609143407 cites W2398110767 @default.
• W2609143407 cites W2465562385 @default.
• W2609143407 cites W2512861430 @default.
• W2609143407 cites W2548352768 @default.
• W2609143407 cites W2585024341 @default.
• W2609143407 cites W2590767446 @default.
• W2609143407 cites W2263357395 @default.
• W2609143407 doi "https://doi.org/10.1371/journal.pone.0176004" @default.
• W2609143407 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5405980" @default.
• W2609143407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28445503" @default.
• W2609143407 hasPublicationYear "2017" @default.
• W2609143407 type Work @default.
• W2609143407 sameAs 2609143407 @default.
• W2609143407 citedByCount "23" @default.
• W2609143407 countsByYear W26091434072018 @default.
• W2609143407 countsByYear W26091434072019 @default.
• W2609143407 countsByYear W26091434072020 @default.
• W2609143407 countsByYear W26091434072021 @default.
• W2609143407 countsByYear W26091434072022 @default.
• W2609143407 countsByYear W26091434072023 @default.
• W2609143407 crossrefType "journal-article" @default.
• W2609143407 hasAuthorship W2609143407A5006130540 @default.
• W2609143407 hasAuthorship W2609143407A5044602450 @default.
• W2609143407 hasAuthorship W2609143407A5052744307 @default.
• W2609143407 hasAuthorship W2609143407A5083131417 @default.
• W2609143407 hasAuthorship W2609143407A5090342457 @default.
• W2609143407 hasBestOaLocation W26091434071 @default.
• W2609143407 hasConcept C126322002 @default.
• W2609143407 hasConcept C197934379 @default.
• W2609143407 hasConcept C203014093 @default.
• W2609143407 hasConcept C203092338 @default.
• W2609143407 hasConcept C2776120307 @default.
• W2609143407 hasConcept C2777199930 @default.
• W2609143407 hasConcept C2778048844 @default.
• W2609143407 hasConcept C2778118209 @default.
• W2609143407 hasConcept C2778371730 @default.
• W2609143407 hasConcept C2778629330 @default.
• W2609143407 hasConcept C2780780316 @default.
• W2609143407 hasConcept C535046627 @default.
• W2609143407 hasConcept C71924100 @default.
• W2609143407 hasConcept C99389464 @default.
• W2609143407 hasConceptScore W2609143407C126322002 @default.
• W2609143407 hasConceptScore W2609143407C197934379 @default.
• W2609143407 hasConceptScore W2609143407C203014093 @default.
• W2609143407 hasConceptScore W2609143407C203092338 @default.
• W2609143407 hasConceptScore W2609143407C2776120307 @default.
• W2609143407 hasConceptScore W2609143407C2777199930 @default.
• W2609143407 hasConceptScore W2609143407C2778048844 @default.
• W2609143407 hasConceptScore W2609143407C2778118209 @default.

• next